Gilead has placed its CAR-T program on partial clinical hold following cases of ICANS, according to the report. The move pauses further enrollment and/or dosing in the affected study setting as the company evaluates safety signals related to the neurological toxicity. In parallel, the same news brief notes that Agios’ PDUFA date has been pushed back, adding to the broader regulatory pressure on oncology timelines. Together, the items underscore how late-stage development plans can shift quickly when immune-toxicity events emerge. For CAR-T investors and competitors, ICANS remains a pacing factor for the field—affecting trial conduct, site readiness, and the cadence of future efficacy readouts. The specific requirements that regulators impose on next steps will likely shape how quickly Gilead can resume broader development.